New studies from Chr. Hansen show that in ovo injection of GalliPro® Hatch — a new probiotic formulation for poultry —may help chicks get a healthier start in life, without affecting hatchability.
The research, along with Chr. Hansen’s expanded range of microbial products and services for poultry, will be showcased at the 2017 International Production and Processing Expo (IPPE) in Atlanta, Georgia, USA.
GalliPro® Hatch is the newest addition to Chr. Hansen’s product portfolio and the company’s first product formulated for in ovo injection. Based on a unique strain of Enterococcus faecium, GalliPro® Hatch has been shown to move rapidly from the injection site to colonize the chick’s developing gut before hatch, improving post-hatch performance.
“Good health starts in the gut, and gut health depends on a well-balanced intestinal microbiome,” explains Alfred Blanch, DVM, PhD, poultry consultant for Chr. Hansen. “Studies show that the unique probiotic strain in GalliPro® Hatch can safely and effectively be injected in ovo, establishing beneficial microbial populations in the gut before hatch and giving chicks a helpful head start on intestinal health.”
Further studies confirm the benefits of probiotics at all stages of broiler production — from hatch, when birds are most vulnerable, to market, when they are most valuable.
“The benefits of probiotic supplementation in poultry production are well documented,” says Fran Jin, PhD, poultry technical manager for North America. “In addition to improving weight gain and feed efficiency, our most recent findings reveal that certain probiotic strains can significantly reduce health and performance losses due to necrotic enteritis and coccidiosis — two of the most common and costly poultry diseases.”
Chr. Hansen’s offerings at IPPE this year will include an exhibitor booth (Hall B, Booth 7729), a technical forum on GalliPro® Hatch and three oral presentations in the International Poultry Scientific Forum (IPSF).
GalliPro® Hatch forum
Veterinarians, nutritionists, researchers and hatchery specialists at IPPE are invited to attend the GalliPro® Hatch forum on Monday, January 30, 2017 from 5-6 p.m. Following a technical overview by poultry consultant Herb Kling, PhD, Aaron Kiess, PhD, poultry science professor at Mississippi State University, will present results from research trials of GalliPro® Hatch. A cocktail reception will follow. To register, please send an email to USKAHA@chr-hansen.com.
The following oral presentations will be given on Tuesday, January 31, 2017, at the 2017 International Poultry Scientific Forum:
- “Confirmation of the presence of Enterococcus faecium M74 in the gastrointestinal tract of young chicks from eggs inoculated with GalliPro® Hatch,” B313, 7:45 a.m.
- “Evaluation of Clostridium perfringens challenged broilers fed Bacillus licheniformis (GalliPro® Tect), Bacillus licheniformis plus Bacillus subtilis (GalliPro® MS) and three other commercial DFMs in a 6-week floor pen study,” B311, 8:45 a.m.
- “Assessment of the effect of a Bacillus licheniformis DFM and a Lactobacillus animalis DFM, alone or together, on the performance of broiler chickens under Eimeria and Clostridium perfringens challenge conditions,” B311, 9:00 a.m.
To view the abstracts, download the 2017 abstract book here and search the titles.
Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on more than 30,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day. Revenue in the 2016/17 financial year was EUR 1,063 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.